RLS Radiopharmacies offers Tc-99m. Place your order at https://lnkd.in/gZnDbxzj ________________________ RLS RADIOPHARMACIES Nationally Accredited. Quality. Reliability. Flexibility. www.rls.bio #rls #rlsradiopharmacies #radiopharmacy #radiopharmaceuticals #nuclearmedicine
RLS Radiopharmacies’ Post
More Relevant Posts
-
For those of you attending the American Thoracic Society Meeting (ATS 2024) in San Diego this week ..if you are pursuing clinical development of investional drugs or devices for Sepsis or its complications I would be interested in chatting or meeting in person .. I led the only Phase III clinical trial of a drug that resulted in FDA approval for sepsis (XIGRIS in 2001). I also played a key role in sepsis trials of recombinant soluble thrombomodulin, anti- TNF monoclonal Ab (Cytofab, Talactoferrin, TLR4 antagonist (E5564) , rTFPI and others #sepsis #ARDS #endotoxin #TNF, #ATS2024
-
Octapharma USA, Inc. has received FDA approval for an expanded indication of our fibrinogen concentrate. This approval allows for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency (AFD). Key highlights: ▪️ First on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication in the US ▪️ Rapid and more precise option for severe bleeding ▪️ Potential to set a new standard of care in the United States This approval stems from the FIBRES study, a robust clinical trial demonstrating non-inferiority to cryoprecipitate. It marks another step in our global mission to provide innovative solutions advancing human life. Read the press release here: https://bit.ly/3Yy3mzf
-
-
Really interesting topics for last week. Definitely there should be more focus on nocebo effect. Pharmacists can provide counseling to ensure patients are aware of what a biosimilar agent is and to set the expectation that they will receive the same level of care with these new agents.
Delivering your dose of the top 5 biosimilar articles of the week! This week's top articles cover exciting developments, including: - Remission in young patients with IBD with biosimilar infliximab - Nocebo effect in patients switching to biosimilar adalimumab - Biosimilar eculizumab for PNH shows promise in reducing transfusions - British Columbia saves millions with their biosimilars initiative - Expert advice on convincing the FDA to streamline biosimilar approvals Don't miss out on these important developments! https://lnkd.in/emK_kaap
-
-
https://lnkd.in/gvrF5MD2 Key Insights: • The approval of Onivyde® regimen (NALIRIFOX) stemmed from the Phase III NAPOLI 3 clinical trial, where it exhibited significant superiority over nab-paclitaxel and gemcitabine, showcasing notable enhancements in overall survival and progression-free survival Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #ipsen #usfda #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
-
Exciting News for Nuclear Medicine! A new rule proposes to unbundle diagnostic radiopharmaceuticals from the current payment system, classifying them separately from "supplies." This will prevent CMS from overpaying for low-cost diagnostics and offer patients access to advanced imaging agents. #nuclearmedicine #radiologynews #healthcare #compuraymedical
There's a new proposed rule that unbundles diagnostic radiopharmaceuticals from the current packaged payment system that classifies them as "supplies." The new rule will prevent CMS from overpaying for low-cost diagnostic radiopharmaceuticals and give patients access to a more precise generation of imaging agents. SNMMI will be submitting a comment in support of the CMS rule and is celebrating this win for patients! Learn more below and on our website: https://lnkd.in/dkPjWqXa
-
Transformational Healthcare Executive | Expert in Radiology & Theranostics | Innovation & Health Equity Champion
Time to comment has started! Let’s do this! Long time coming, and significant amount of lobbying to get us to this point. Kudos!! 🤞🤞🤞🤞🤞🤞🤞🤞🤞 #radiopharmaceuticals #nuclearmedicine #theranostics #radioligandtherapy #radiology #precisionmedicine
There's a new proposed rule that unbundles diagnostic radiopharmaceuticals from the current packaged payment system that classifies them as "supplies." The new rule will prevent CMS from overpaying for low-cost diagnostic radiopharmaceuticals and give patients access to a more precise generation of imaging agents. SNMMI will be submitting a comment in support of the CMS rule and is celebrating this win for patients! Learn more below and on our website: https://lnkd.in/dkPjWqXa
-
Discover how GLP-1 receptor agonists, like semaglutide, work to provide a scientifically proven approach to weight management. Read More: https://lnkd.in/eUU2yq2h #Myhealthvio #PharmacySuccess #PharmacyPartner #PharmacyGrowth #HealthSolutions #PharmacyRevenue #PharmacyBusiness #HealthInnovation #FDAApproved #CustomerLoyalty #HealthPartners #PharmacyLife #WellnessSolutions #PharmacyCare #PharmacySupport #Semaglutide #GLP1 #tizepatide #revenue #independentpharmacies
-
-
Ensuring biomolecule stability is easier than ever before with high-throughput, high-concentration testing on the new RS-DSC. See how it works in this 6-minute demo video: https://lnkd.in/eSQYEjVN #Biopharma #DrugDiscovery #Antibodies
-
READ NOW: NAVLIN Last Week in Review https://ow.ly/KW7150SsPgf This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world: Policy: Learn how new criteria could impact market access and treatments like Gilead’s Trodelvy. Pricing & Reimbursement Discover how Vertex’s long-term agreement with NHS England marks a new era for cystic fibrosis treatment availability. HTA: Learn how CSL Behring’s Hemgenix is set to transform the treatment landscape for adults with severe hemophilia B, following NICE’s final draft guidance. Other: Discover how the EMA and HMA are addressing shortages of key GLP-1 receptor agonists like Ozempic, Saxenda, Trulicity, and Victoza. And more... #NAVLIN #CysticFibrosis #HemophiliaBTreatment #MarketAccess #DrugEvaluation
-
-
🌟 Exciting breakthrough in lupus treatment! Synthekine has received FDA clearance for their innovative SYNCAR-001 + STK-009 combo therapy, marking a new era in lupus care without lymphodepletion (no chemotherapy!)🌟 This pioneering approach targets non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN) with a unique orthogonal IL-2 and CD19 CAR-T therapy. With Synthekine’s orthoIL-2 technology, this treatment promises controlled cell expansion and a highly differentiated option for patients. 🚀 The upcoming Phase 1 study aims to assess safety and clinical activity, with patient enrollment expected in late 2024. This could be a game-changer for those battling lupus! 💡 #Synthekine #LupusTreatment #FDAApproval #ClinicalTrials #Immunotherapy #CytokineTherapeutics #CD19CART #IL2Therapy #SystemicLupusErythematosus #LupusNephritis #AutoimmuneDiseases #Biotech #HealthcareInnovation #MedicalResearch #DrugDevelopment #PatientCare #HealthTech #Biopharma #LifeSciences #InflammatoryDiseases #Oncology #Immunology #Pharmaceuticals #Medicine #Therapeutics #Healthcare #lupus #SLE #chemo #biotech #innovation
Today, we announced the U.S. FDA clearance of our Investigational New Drug (IND) application for SYNCAR-001 + STK-009, an orthogonal IL-2 and CD19 #CART combination therapy, in patients with non-renal systemic lupus erythematosus (#SLE) and lupus nephritis (#LN), without the use of lymphodepletion. We look forward to leveraging the potential of our orthoIL-2 technology to provide safer, more effective treatment for patients and overcome the burdens associated with #lymphodepletion. Learn more: https://bit.ly/43Pd8Od #celltherapy #INDacceptance #Lupus #cytokinescience
